Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Lel H who wrote (120)	3/3/1999 7:55:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1834

Based on the conference call, it looks like about $12 million is guaranteed; $5 million this year (maybe 2million licensing, plus 3million R&D), "$3-4 million" for the next two years R&D support. But it also seems that some early milestone payments may occur, sinc another $2-3 million could come in 1999. So it is 2 plus years before one can even consider an IND, but it does fund another 15-20 of NBIX's personnel. I had zero built into the NBIX model from DHEA; it would have been a nice plus, albeit a challenge to market given the ubiquitous presence of DHEA in health food stores--but nothing that was being counted upon. NeuroInvestment (www.neuroinvestment.com)